3 results
Part I of this study is designed to identify the recommended phase 2 dose of the combination regimen of galunisertib/capecitabine as second line treatment in patients with 5-FU or capecitabine resistant colorectal carcinoma. Part II is designed to…
Primary Objective: to use psilocybin as a research tool in order to enhance divergent thinking, and facilitate relative goal-directed versus habitual behaviour during and after drug intoxication, and to assess whether psilocybin will deter a stress…
With this clinical study, we aim to gain more information about the pharmacological characteristics, safety profile, tolerability and efficacy of galunisertib in combination with capecitabine in patients with PM from CRC. The ultimate goal is to…